Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9397608 | Annales d'Urologie | 2005 | 4 Pages |
Abstract
The efficacy and safety of triptorelin acetate (Decapeptyl®) administered at a dose of 11.25 mg every trimester for one year were evaluated in a European multicentre open trial including 54 girls and 10 boys. The LH peak during the GnRH test at three months was used as primary end-point. This slow release triptorelin was shown to be effective, similarly to delayed-acting leuprorelin. The auxological effects, in particular on adult height, were not evaluated in this study.
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Jean-Claude Carel,